These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35466584)

  • 1. Clinical features and prognosis according to genomic mutations in primary and metastatic lesions of non-small-cell lung cancer.
    Zhang W; Han W; Yu B; Zhao X; Lu G; Wu W; Zhang Y
    Thorac Cancer; 2022 Jun; 13(11):1642-1650. PubMed ID: 35466584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
    Chen M; Xu Y; Zhao J; Zhong W; Zhang L; Bi Y; Wang M
    EBioMedicine; 2019 Apr; 42():304-310. PubMed ID: 30878600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The expression of programmed death receptor 1 in non-small cell lung cancer and its clinicopathological features and prognosis showed a connection with epidermal growth factor receptor gene mutations].
    Yin H; Liao CG; Wang YQ; Li Z; Fan LL; Qian ML; Lu N
    Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):419-423. PubMed ID: 28635230
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinicopathological features and EGFR gene mutation status in elderly patients with resected non-small-cell lung cancer.
    Nishii T; Yokose T; Miyagi Y; Daigo Y; Ito H; Isaka T; Imai K; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Tsuboi M; Nakayama H; Masuda M
    BMC Cancer; 2014 Aug; 14():610. PubMed ID: 25152277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
    Qin K; Hou H; Liang Y; Zhang X
    BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genes associated with increased brain metastasis risk in non-small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036).
    Wang H; Ou Q; Li D; Qin T; Bao H; Hou X; Wang K; Wang F; Deng Q; Liang J; Zheng W; Wu X; Wang X; Shao YW; Mou Y; Chen L
    Cancer; 2019 Oct; 125(20):3535-3544. PubMed ID: 31287555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated genomic and DNA methylation analysis of patients with advanced non-small cell lung cancer with brain metastases.
    Xu Y; Huang Z; Yu X; Chen K; Fan Y
    Mol Brain; 2021 Dec; 14(1):176. PubMed ID: 34952628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity and Clinical Effect of Epidermal Growth Factor Receptor in Primary Lung and Brain Metastases of Nonsmall Cell Lung Cancer.
    Xu S; Zhu J; Zhong D; Wang W; Wen Y; Zhang L; Jiang T
    J Surg Res; 2023 Mar; 283():674-682. PubMed ID: 36459860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of epidermal growth factor receptor and KRAS gene status between primary and corresponding metastatic tumours of non-small cell lung cancer.
    Wang S; Wang Z
    Clin Oncol (R Coll Radiol); 2015 Jan; 27(1):30-9. PubMed ID: 25445553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations.
    Wang H; Wang Z; Zhang G; Zhang M; Zhang X; Li H; Zheng X; Ma Z
    Cancer Med; 2020 Jan; 9(2):487-495. PubMed ID: 31769228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
    Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
    Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer.
    Gow CH; Chang YL; Hsu YC; Tsai MF; Wu CT; Yu CJ; Yang CH; Lee YC; Yang PC; Shih JY
    Ann Oncol; 2009 Apr; 20(4):696-702. PubMed ID: 19088172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics.
    Tan DS; Camilleri-Broët S; Tan EH; Alifano M; Lim WT; Bobbio A; Zhang S; Ng QS; Ang MK; Iyer NG; Takano A; Lim KH; Régnard JF; Tan P; Broët P
    Int J Cancer; 2014 Sep; 135(5):1092-100. PubMed ID: 24482041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).
    Lim SM; Kim HR; Cho EK; Min YJ; Ahn JS; Ahn MJ; Park K; Cho BC; Lee JH; Jeong HC; Kim EK; Kim JH
    Oncotarget; 2016 Jun; 7(24):36311-36320. PubMed ID: 27121209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between epidermal growth factor receptor gene mutations and clinicopathological features in patients with non-small cell lung cancer in western Turkey.
    Unal OU; Oztop I; Calibasi G; Baskin Y; Koca D; Demir N; Akman T; Ellidokuz H; Yilmaz AU
    Asian Pac J Cancer Prev; 2013; 14(6):3705-9. PubMed ID: 23886169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
    Lai GGY; Lim TH; Lim J; Liew PJR; Kwang XL; Nahar R; Aung ZW; Takano A; Lee YY; Lau DPX; Tan GS; Tan SH; Tan WL; Ang MK; Toh CK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Yuan J; Lim TKH; Lim AST; Hillmer AM; Lim WT; Iyer NG; Tam WL; Zhai W; Tan EH; Tan DSW
    J Clin Oncol; 2019 Apr; 37(11):876-884. PubMed ID: 30676858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
    Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?
    Mansuet-Lupo A; Zouiti F; Alifano M; Tallet A; Charpentier MC; Ducruit V; Devez F; Lemaitre F; Laurent-Puig P; Damotte D; Blons H
    J Transl Med; 2014 May; 12():131. PubMed ID: 24885034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
    Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
    Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.